- Home
- ASPI vs VIR Comparison
ASPI vs VIR Comparison
Compare ASPI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPI
- VIR
- Stock Information
- Founded
- ASPI 2021
- VIR 2016
- Country
- ASPI United States
- VIR United States
- Employees
- ASPI N/A
- VIR 408
- Industry
- ASPI Major Chemicals
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- ASPI Industrials
- VIR Health Care
- Exchange
- ASPI Nasdaq
- VIR Nasdaq
- Market Cap
- ASPI 653.4M
- VIR 706.4M
- IPO Year
- ASPI 2022
- VIR 2019
- Fundamental
- Price
- ASPI $6.84
- VIR $5.86
- Analyst Decision
- ASPI Strong Buy
- VIR Strong Buy
- Analyst Count
- ASPI 2
- VIR 7
- Target Price
- ASPI $7.75
- VIR $32.86
- AVG Volume (30 Days)
- ASPI 3.6M
- VIR 1.1M
- Earning Date
- ASPI 08-18-2025
- VIR 07-31-2025
- Dividend Yield
- ASPI N/A
- VIR N/A
- EPS Growth
- ASPI N/A
- VIR N/A
- EPS
- ASPI N/A
- VIR N/A
- Revenue
- ASPI $4,405,477.00
- VIR $20,861,000.00
- Revenue This Year
- ASPI $512.64
- VIR N/A
- Revenue Next Year
- ASPI $181.15
- VIR N/A
- P/E Ratio
- ASPI N/A
- VIR N/A
- Revenue Growth
- ASPI 245.97
- VIR N/A
- 52 Week Low
- ASPI $1.86
- VIR $4.32
- 52 Week High
- ASPI $10.08
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- ASPI 45.07
- VIR 58.23
- Support Level
- ASPI $6.59
- VIR $5.20
- Resistance Level
- ASPI $7.24
- VIR $5.49
- Average True Range (ATR)
- ASPI 0.53
- VIR 0.25
- MACD
- ASPI -0.12
- VIR 0.03
- Stochastic Oscillator
- ASPI 25.00
- VIR 88.73
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.